Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,111
  • Shares Outstanding, K 71,618
  • Annual Sales, $ 49,570 K
  • Annual Income, $ -42,470 K
  • 60-Month Beta 1.43
  • Price/Sales 0.87
  • Price/Cash Flow N/A
  • Price/Book 4.57
Trade CDTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.55
  • Most Recent Earnings 0.17 on 11/03/22
  • Next Earnings Date 11/09/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -901.20%)
  • Historical Volatility 72.80%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,118.42% on 07/26/22
  • IV Low 0.00% on 12/07/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,049
  • Open Int (30-Day) 820

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +96.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5201 +7.31%
on 11/11/22
0.7400 -24.58%
on 11/28/22
-0.0019 (-0.34%)
since 11/07/22
3-Month
0.5201 +7.31%
on 11/11/22
0.8058 -30.74%
on 09/16/22
-0.1073 (-16.13%)
since 09/07/22
52-Week
0.4000 +39.52%
on 06/06/22
1.7100 -67.36%
on 12/10/21
-1.0719 (-65.76%)
since 12/07/21

Most Recent Stories

More News
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

CDTX : 0.5581 (-5.09%)
ABSI : 2.55 (unch)
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 0.5581 (-5.09%)
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CDTX : 0.5581 (-5.09%)
LVTX : 5.87 (-6.53%)
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.5581 (-5.09%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DNLI : 30.10 (-1.18%)
CDTX : 0.5581 (-5.09%)
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

XOMA : 19.03 (-2.36%)
CDTX : 0.5581 (-5.09%)
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SRPT : 119.76 (-0.28%)
CDTX : 0.5581 (-5.09%)
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BIIB : 292.15 (+0.23%)
CDTX : 0.5581 (-5.09%)
Cidara Therapeutics to Host Research and Development Day

Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th...

CDTX : 0.5581 (-5.09%)
Cidara Therapeutics to Host Research and Development Day

Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on Thursday, July 7th...

CDTX : 0.5581 (-5.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 0.6481
2nd Resistance Point 0.6240
1st Resistance Point 0.5911
Last Price 0.5581
1st Support Level 0.5341
2nd Support Level 0.5100
3rd Support Level 0.4771

See More

52-Week High 1.7100
Fibonacci 61.8% 1.2096
Fibonacci 50% 1.0550
Fibonacci 38.2% 0.9004
Last Price 0.5581
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar